Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High ‐Grade Gliomas: A Nested Case‐Control Study

ConclusionWe found no significant association between use of bevacizumab and occurrence of thromboembolic events in patients with high ‐grade gliomas, although our study was limited by the small number of ATE events. Since the potential for complications from arterial thrombosis cannot be completely ruled out, further research is needed to confirm the thromboembolic safety of bevacizumab in a larger sample of patients with high‐ grade gliomas.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2019 Category: Drugs & Pharmacology Authors: Inyoung Lee, Sruthi Adimadhyam, Edith A. Nutescu, Jifang Zhou, Alemseged A. Asfaw, Karen Sweiss, Pritesh R. Patel, Gregory S. Calip Tags: Brief Report Source Type: research